Selective serotonin reuptake inhibitors (SSRIs) are commonly used as first-line therapy to treat mood disorders due to their demonstrated efficacy, safety, and tolerability profiles. SSRIs may play an intricate role in treating hormone-mediated disorders that disturb the quality of life for women. Selected uses of SSRIs, specifically in the treatment of hot flashes, premenstrual dysphoric disorder, and postpartum depression, are explored in this article. Data from several studies support the use of SSRIs in these conditions, and therefore, these agents have the potential to significantly improve mood, cognitive function, physical symptoms, and social functioning in patients with these disorders. In addition, SSRIs may prove to be viable alternatives to current therapies that may be contraindicated, poorly tolerated, or lack efficacy in patients with these disorders.
Get full access to this article
View all access options for this article.
References
1.
1. Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer . J Pain Symptom Manage. 2000;19: 436-445 .
2.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial . JAMA. 2002;288: 321-333 .
3.
3. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes . J Clin Oncol. 2002;20: 1578-1583 .
4.
4. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine . Arch Gen Psychiatry. 2000;57: 503-509 .
5.
5. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial . Lancet. 2000;356: 2059-2063 .
6.
6. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors . J Clin Oncol. 1998;16: 2377-2381 .
7.
7. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors . Ann Oncol. 2000;11: 17-22 .
8.
8. Weitzner MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer . J Pain Symptom Manage. 2002;23: 337-345 .
9.
9. Stewart AL, Ware JE, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press ; 1992.
10.
10. Frakiewicz EJ, Shiovitz TM. Evaluation and management of premenstrual syndrome dysphoric disorder . J Am Pharm Assoc. 2001;3: 437 . Abstract.
11.
11. Kessel B. Premenstrual syndrome: advances in diagnosis and treatment . Obstet Gynecol Clin North Am. 2000;27: 625-639 .
12.
12. Frye GM, Silverman SD. Is it premenstrual syndrome? Keys to focused diagnosis, therapies for multiple symptoms . Postgrad Med. 2000;107: 151-154, 157-159 .
13.
13. Brown ES, Khan DA, Mahadi S. Psychiatric diagnoses in inner city outpatients with moderate to severe asthma . Int J Psychiatry Med. 2000;30: 319-327 .
14.
14. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group . N Engl J Med. 1995;332: 1529-1534 .
15.
15. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial . J Clin Psychiatry. 1998;59: 76-80 .
16.
16. Sarafem [package insert]. Indianapolis, IN: Eli Lilly; 2001.
17.
17. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder . J Clin Psychiatry. 1994;55: 332-335 .
18.
18. Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder . J Clin Psychopharmacol. 1997;17: 261-266 .
19.
19. Guy W. ECDEU Assessment Manual For Psychopharmacology. Rockville, MD: National Institute of Mental Health, US Department of Health, Education and Welfare ; 1976. Publication ADM76-338: 217-222.
20.
20. Hamilton M. A rating scale for depression . J Neurol Neurosurg Psychiatry. 1960;23: 56-62 .
21.
21. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance . Arch Gen Psychiatry. 1976;33: 766-771 .
22.
22. Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria . Neuropsychopharmacology. 1997;16: 346-356 .
23.
23. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study . Obstet Gynecol. 1992;80: 339-344 .
24.
24. Lin J, Thompson DS. Treating premenstrual dysphoric disorder using serotonin agents . J Womens Health Gend Based Med. 2001;10: 745-750 .
25.
25. Menkes DB, Taghavi E, Mason PA, Spears GF, Howard RC. Fluoxetine treatment of severe premenstrual syndrome . BMJ. 1992;305: 346-347 .
26.
26. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of premenstrual syndrome . Psychopharmacol Bull. 1990; 26: 331-335 .
27.
27. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria . Psychopharmacol Bull. 1997;33: 771-774 .
28.
28. Daamen MJ, Brown WA. Single-dose fluoxetine in management of premenstrual syndrome . J Clin Psychiatry. 1992;53: 210-211 .
29.
29. Zoloft. [package insert]. New York, NY: Pfizer, Inc; 2002.
30.
30. Yonkers KA, Halbreich U, Freeman E, Brown C, Pearlstein T. Sertraline in the treatment of premenstrual dysphoric disorder . Psychopharmacol Bull. 1996;32: 41-46 .
31.
31. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo . J Clin Psychiatry. 2000;61: 101-109 .
32.
32. Endicott JH, W. Daily Rating of Severity of Problems Form. New York, NY: Department of Research Assessment and Training, New York State Psychiatric Institute ; 1990.
33.
33. Weissman MB, S. Assessment of social adjustment by patient self-report . Arch Gen Psychiatry. 1976;33: 1111-1115 .
34.
34. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure . Psychopharmacol Bull. 1993;29: 321-326 .
36. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study . Arch Fam Med. 1999;8: 328-332 .
37.
37. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder . J Clin Psychopharmacol. 1996;16: 3-8 .
38.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association ; 1994.
39.
39. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome . Neuropsychopharmacology. 1995;12: 167-176 .
40.
40. Freeman EW, Jabara S, Sondheimer SJ, Auletto R. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study . J Womens Health Gend Based Med. 2002;11: 459-464 .
41.
41. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;18: 390-398 .
42.
42. Hutchison TA, Shahan DR, eds. DRUGDEX(r) System. MICROMEDEX, Greenwood Village, Colo . (Edition expires October 2002).
43.
43. Freeman EW, Rickels K, Sondheimer SJ. Fluvoxamine for premenstrual dysphoric disorder: a pilot study . J Clin Psychiatry. 1996;57(suppl 8): 56-59 ; discussion 60.
44.
44. Veeninga AT, Westenberg HG, Weusten JT. Fluvoxamine in the treatment of menstrually related mood disorders . Psychopharmacology. (Berl)1990;102: 414-416 .
45.
45. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Health Disorders. Washington, DC: American Psychiatric Association ; 1987.
46.
46. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Life-time prevalence, chronicity and recurrence . J Affect Disord. 1993;29: 85-96 .
47.
47. Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HU. Sex differences in rates of depression: cross-national perspectives . J Affect Disord. 1993;29: 77-84 .
48.
48. Altshuler LL. The use of SSRIs in depressive disorders specific to women . J Clin Psychiatry. 2002;63(suppl 7): 3-8 .
49.
49. Richards JP. Postnatal depression: a review of recent literature . Br J Gen Pract. 1990;40: 472-476 .
50.
50. Cooper PJ, Murray L. Course and recurrence of postnatal depression: evidence for the specificity of the diagnostic concept . Br J Psychiatry. 1995;166: 191-195 .
52. O'Hara MW, Schlechte JA, Lewis DA, Varner MW. Controlled prospective study of postpartum mood disorders: psychological, environmental, and hormonal variables . J Abnorm Psychol. 1991;100: 63-73 .
53.
53. American Psychiatric Association, American Psychiatric Association, Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association ; 2000:xxxvii, 943.
54.
54. Wisner KL, Parry BL, Piontek CM. Clinical practice. Postpartum depression . N Engl J Med. 2002;347: 194-199 .
55.
55. Suri R, Burt VK. The assessment and treatment of postpartum psychiatric disorders . J Pract Psychiatry Behav Health. 1997;3: 67-77 .
56.
56. O'Hara MW, Schlechte JA, Lewis DA, Wright EJ. Prospective study of postpartum blues: biologic and psychosocial factors . Arch Gen Psychiatry. 1991;48: 801-806 .
57.
57. Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period . J Clin Psychiatry. 1998;59(suppl 2): 29-33 .
58.
58. Watson JP, Elliott SA, Rugg AJ, Brough DI. Psychiatric disorder in pregnancy and the first postnatal year . Br J Psychiatry. 1984; 144: 453-462 .
59.
59. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs . Psychiatry Res. 1986;17: 87-95 .
60.
60. Kornstein SG. Gender differences in depression: implications for treatment . J Clin Psychiatry. 1997;58(suppl 15): 12-18 .
61.
61. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression . Am J Psychiatry. 2000;157: 1445-1452 .
62.
62. Raskin A. Age-sex differences in response to antidepressant drugs . J Nerv Ment Dis. 1974;159: 120-130 .
63.
63. Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression . BMJ. 1997;314: 932-936 .
64.
64. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the 10-item Edinburgh Postnatal Depression Scale . Br J Psychiatry. 1987;150: 782-786 .
65.
65. Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers . Psychol Med. 1992;22: 465-486 .
66.
66. Hamilton M. Hamilton Psychiatric Rating Scale for Depression. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare ; 1976:179-192.
67.
67. Roy A, Cole K, Goldman Z, Barris M. Fluoxetine treatment of postpartum depression . Am J Psychiatry. 1993;150: 1273 .
68.
68. Beck AT, Steer RA, Garbing MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation . Clin Psychol Rev.1988;8: 77-100 .
69.
69. Suri R, Burt VK, Altshuler LL, Zuckerbrow-Miller J, Fairbanks L. Fluvoxamine for postpartum depression . Am J Psychiatry. 2001;158: 1739-1740 .
70.
70. Stowe Z, Casarella J, Landry J, Nemeroff CB. Sertraline in the treatment of women with postpartum major depression . Depression. 1995;3: 49-55 .
71.
71. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale . Arch Gen Psychiatry. 1988;45: 742-747 .
72.
72. Cohen LS, Viguera AC, Bouffard SM, et al. Venlafaxine in the treatment of postpartum depression . J Clin Psychiatry. 2001;62: 592-596 .
73.
73. Kellner R. A symptom questionnaire . J Clin Psychiatry. 1987;48: 268-274 .
74.
74. Newport DJ, Hostetter A, Arnold A, Stowe ZN. The treatment of postpartum depression: minimizing infant exposures . J Clin Psychiatry. 2002;63(suppl 7): 31-44 .
75.
75. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. The use of psychotropic medications during breast-feeding . Am J Psychiatry. 2001;158: 1001-1009 .
76.
76. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding . Am J Psychiatry. 1996;153: 1132-1137 .
77.
77. Burnham TH, Short RM, Bell WL, Schweain SL, eds. Drugs Facts and Comparisons Pocket Version. 6th ed. St. Louis, Mo: A Wolters Kluwer Company ; 2002:545, 550-555.
